NCT01245751View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

May 31, 2015

Conditions
Herpes ZosterVaricella-zoster Vaccine
Interventions
BIOLOGICAL

Zoster Vaccine, Live

Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Duke University

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01245751 - Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) | Biotech Hunter | Biotech Hunter